A Phase 1/2 interventional study of Dasatinib and Lomustine in Glioblastoma, sponsored by Bristol-Myers Squibb. Terminated at 5 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-08-31.
Sponsored by Bristol-Myers Squibb · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing lomustine in Glioblastoma — 3 open to participants now, 4 under way, 2 of them phase 3. Lomustine · Glioblastoma.
Among the 22 studies testing lomustine in Glioblastoma, this one is the 16th largest by enrollment, is the only one that started in 2009, is one of 2 in phase 1/2, and was the 5th registered.
2,135 studies on the registry are indexed under Glioblastoma; 467 are open to participants now.
Browse Glioblastoma studies →3 of the 22 studies testing lomustine in Glioblastoma are open now, in 5 countries. Recruiting first, the newest first:
University of California, Davis · Sites in United States
Ages 18+
Vastra Gotaland Region · Sites in Austria, Denmark, Norway and 1 more country
Ages 18–70
The University of Texas Health Science Center at San Antonio · Sites in United States
By country, each count listing its studies:
Lomustine: first FDA approval 1976 (GLEOSTINE). What it is approved for, and how studies give it, is on its page →
Of the 339 Glioblastoma studies recruiting now, 234 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 12 · Phase 3 5
First in 2002; this study’s year is marked. 1 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 28 is below the median of 36 across 1,756 interventional studies indexed under Glioblastoma.
Median enrollment 68 across the 22 interventional studies. Of the 14 that completed or were terminated, 8 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 22 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
14 studies in Glioblastoma by Bristol-Myers Squibb: 1 open now, 1 under way, none of them phase 3. Of 11 finished, 4 (36%) have results posted.
Among the 14 studies in Glioblastoma by Bristol-Myers Squibb, this one is the 13th largest by enrollment, is the only one that started in 2009, is one of 4 in phase 1/2, and was the 4th registered.
Bristol-Myers Squibb’s Glioblastoma studies by the year they started, since 2003.
1 of the studies testing lomustine in Glioblastoma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07145112University of California, DavisLaser Interstitial Thermal Therapy (LITT) and Lomustine (CCNU) for Recurrent Glioblastoma | 2027-03 |
Add it to your calendar (.ics) → With an account.
Among the 22 studies testing lomustine in Glioblastoma, from their registry updates:
Among Bristol-Myers Squibb’s 14 in Glioblastoma:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To determine whether dasatinib plus lomustine are effective for treatment of recurrent glioblastoma
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Dasatinib
Drug: Lomustine
Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Deaths, and Discontinuations Due to AEs
SAE=any untoward medical event that results in death, persistent or significant disability/incapacity, or drug dependency or abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires inpatient hospitalization or prolongation. AE=any new untoward medical occurrence or worsening of a preexisting medical condition that does not necessarily have a causal relationship with this treatment. Treatment-related(Tx-R)=certainly, probably, possibly related and unknown relationship to study drug. AE grades(Gr) 1=Mild; 2=Moderate; 3=Severe; 4=Life-threatening.
Time frame: Assessed at baseline, every 2 weeks during cycles 1-6 (6-week cycles), and every 6 weeks after cycle 6. Median number of cycles = 1.0 (range: 1.0 - 7.0).
Number of Participants With Dose-limiting Toxicities (DLTs)
Grades (gr) according to National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI CTCAE), version 3.0. DLTs were defined as adverse drug reactions as follows: absolute neutrophil counts \<0.5x10\^9/L (gr4) lasting for 7 consecutive days; febrile neutropenia (neutrophil count \<1x10\^9/L and fever of \>=38.5°C); thrombocytopenia (gr4); any gr3/4 nonhematological toxicity except nausea, vomiting and fever which could be rapidly controlled with appropriate measures; any toxicity which did not allow administering at least 70% of the intended dose intensity for both agents.
Time frame: The duration for observation of DLT was 2 6-week cycles in participants with escalated dose (QD to BID) and 1 6 -week cycle for participants starting with BID regime. For participants receiving dasatinib at 150 mg, DLTs were only documented over cycle 1.
Deaths Within 30 Days of Protocol Treatment Discontinuation
Time frame: From time of randomization through within 30 days after protocol treatment discontinuation. Median (full range) number of 6-week treatment cycles was 1.0 (1.0-7.0).
Number of Participants With Worst Grade of Hematological Toxicity Per NCI CTCAE Version 3.0 Criteria
Neutrophils (neutropenia): Grade (gr)1 \<LLN-1500/mm3; Gr2 \<1500-1000/mm3; Gr3 \<1000-500/mm3; Gr4 \<500/mm3. Leukocytes (leukopenia): Gr1 \<LLN-3000/mm3; Gr2 \<3000-2000/mm3; Gr3 \<2000-1000/mm3; Gr4 \<1000/mm3. Lymphocytes (lymphocytopenia): Gr1 \<LLN-800/mm3; Gr2 \<800-500/mm3; Gr3 \<500-200/mm3; Gr4 \<200/mm3. Platelets (thrombocytopenia): Gr1 \<LLN-75,000/mm3; Gr2 \<75,000-50,000/mm3; Gr3 \<50,000-25,000/mm3; Gr4 \<25,000/mm3. Hemoglobin (anemia): Gr1 \<LLN-10.0 g/dL; Gr2 \<10.0-8.0 g/dL; Gr3 \<8.0-6.5 g/dL; Gr4 \<6.5 g/dL. LLN/ULN=lower/upper limit of normal (normal ranges may vary by local laboratories).
Time frame: Assessed at baseline, every 2 weeks during cycles 1-6 (6-week cycles), and every 6 weeks after cycle 6. Median number of cycles = 1.0 (range: 1.0 - 7.0).
Number of Participants With Worst Grade of Biochemistry Abnormality Per NCI CTCAE Version 3.0 Criteria
Grades (gr) 1=mild; gr2=moderate; gr3=severe; gr4=life-threatening. For details of NCI CTCAE laboratory values for each grade, please refer to http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_30. Low Potassium=Hypokalemia, High Potassium=Hyperkalemia, Low Sodium=Hyponatremia, Low Calcium=Hypocalcemia, High Bilirubin=Hyperbilirubinemia, low phosphatase=Hypophosphatemia, Low Potassium=Hypokalemia.
Time frame: Assessed at baseline, every 2 weeks during cycles 1-6 (6-week cycles), and every 6 weeks after 6 cycles. Median number of cycles = 1.0 (range: 1.0 - 7.0).
Number of Participants With Disease Progression at 12 Months
As measured by brain magnetic resonance imaging.
Time frame: 12 months
| Milestone | Dasatinib, 100 mg QD/100 mg BID + Lomustine, 110 mg/m^2 | Dasatinib, 100 mg QD/100 mg BID + Lomustine, 90 mg/m^2 | Dasatinib, 100 mg BID + Lomustine, 90 mg/m^2 | Dasatinib, 150 mg/d + Lomustine, 90 mg/m^2 | Dasatinib, 100 mg/d QD + Lomustine, 90 mg/m^2 |
|---|---|---|---|---|---|
| Started | 6 | 3 | 7 | 9 | 1 |
| Completed | 0 | 0 | 0 | 0 | 0 |
| Not completed | 6 | 3 | 7 | 9 | 1 |
| Withdrew: Disease progression/relapse/death | 3 | 3 | 7 | 8 | 1 |
| Withdrew: Thrombocytopenia, grade 4 | 2 | 0 | 0 | 1 | 0 |
| Withdrew: Both progression and toxicity | 1 | 0 | 0 | 0 | 0 |
SAE=any untoward medical event that results in death, persistent or significant disability/incapacity, or drug dependency or abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires inpatient hospitalization or prolongation. AE=any new untoward medical occurrence or worsening of a preexisting medical condition that does not necessarily have a causal relationship with this treatment. Treatment-related(Tx-R)=certainly, probably, possibly related and unknown relationship to study drug. AE grades(Gr) 1=Mild; 2=Moderate; 3=Severe; 4=Life-threatening.
| participants | Dasatinib, 100 mg QD/100 mg BID + Lomustine, 110 mg/m^2 | Dasatinib, 100 mg QD/100 mg BID + Lomustine, 90 mg/m^2 | Dasatinib, 100 mg BID + Lomustine, 90 mg/m^2 | Dasatinib, 150 mg/d + Lomustine, 90 mg/m^2 | Dasatinib, 100 mg/d QD + Lomustine, 90 mg/m^2 |
|---|---|---|---|---|---|
| Deaths within 30 days of Tx Discontinuation | 1 | 0 | 1 | 0 | 0 |
| Tx-R Deaths within 30 days of Tx Discontinuation | 0 | 0 | 0 | 0 | 0 |
| At Least 1 SAE | 5 | 1 | 4 | 4 | 0 |
| At Least 1 Tx-R SAE | 4 | 0 | 1 | 1 | 0 |
| Discontinuations Due to AEs | 3 | 0 | 0 | 1 | 0 |
| At Least 1 AE | 6 | 3 | 7 | 9 | 1 |
| At Least 1 Gr 3/4 AE | 2 | 2 | 4 | 4 | 0 |
| At Least 1 Tx-R AE | 5 | 2 | 5 | 7 | 1 |
| At Least 1 Tx-R Gr 3/4 AE | 0 | 0 | 0 | 0 | 0 |
Grades (gr) according to National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI CTCAE), version 3.0. DLTs were defined as adverse drug reactions as follows: absolute neutrophil counts \<0.5x10\^9/L (gr4) lasting for 7 consecutive days; febrile neutropenia (neutrophil count \<1x10\^9/L and fever of \>=38.5°C); thrombocytopenia (gr4); any gr3/4 nonhematological toxicity except nausea, vomiting and fever which could be rapidly controlled with appropriate measures; any toxicity which did not allow administering at least 70% of the intended dose intensity for both agents.
| participants | Dasatinib, 100 mg QD/100 mg BID + Lomustine, 110 mg/m^2 | Dasatinib, 100 mg QD/100 mg BID + Lomustine, 90 mg/m^2 | Dasatinib, 100 mg BID + Lomustine, 90 mg/m^2 | Dasatinib, 150 mg/d + Lomustine, 90 mg/m^2 | Dasatinib, 100 mg/d QD + Lomustine, 90 mg/m^2 |
|---|---|---|---|---|---|
| Number of Participants With Dose-limiting Toxicities (DLTs) | 3 | — | 3 | 4 | — |
| participants | Dasatinib, 100 mg QD/100 mg BID + Lomustine, 110 mg/m^2 | Dasatinib, 100 mg QD/100 mg BID + Lomustine, 90 mg/m^2 | Dasatinib, 100 mg BID + Lomustine, 90 mg/m^2 | Dasatinib, 150 mg/d + Lomustine, 90 mg/m^2 | Dasatinib, 100 mg/d QD + Lomustine, 90 mg/m^2 |
|---|---|---|---|---|---|
| Deaths Within 30 Days of Protocol Treatment Discontinuation | 1 | 0 | 1 | 0 | 0 |
Neutrophils (neutropenia): Grade (gr)1 \<LLN-1500/mm3; Gr2 \<1500-1000/mm3; Gr3 \<1000-500/mm3; Gr4 \<500/mm3. Leukocytes (leukopenia): Gr1 \<LLN-3000/mm3; Gr2 \<3000-2000/mm3; Gr3 \<2000-1000/mm3; Gr4 \<1000/mm3. Lymphocytes (lymphocytopenia): Gr1 \<LLN-800/mm3; Gr2 \<800-500/mm3; Gr3 \<500-200/mm3; Gr4 \<200/mm3. Platelets (thrombocytopenia): Gr1 \<LLN-75,000/mm3; Gr2 \<75,000-50,000/mm3; Gr3 \<50,000-25,000/mm3; Gr4 \<25,000/mm3. Hemoglobin (anemia): Gr1 \<LLN-10.0 g/dL; Gr2 \<10.0-8.0 g/dL; Gr3 \<8.0-6.5 g/dL; Gr4 \<6.5 g/dL. LLN/ULN=lower/upper limit of normal (normal ranges may vary by local laboratories).
| participants | Dasatinib, 100 mg QD/100 mg BID + Lomustine, 110 mg/m^2 | Dasatinib, 100 mg QD/100 mg BID + Lomustine, 90 mg/m^2 | Dasatinib, 100 mg BID + Lomustine, 90 mg/m^2 | Dasatinib, 150 mg/d + Lomustine, 90 mg/m^2 | Dasatinib, 100 mg/d QD + Lomustine, 90 mg/m^2 |
|---|---|---|---|---|---|
| At least 1 Grade 1-4 Neutropenia | 3 | 2 | 2 | 5 | 0 |
| At least 1 Grade 1-4 Leukopenia | 5 | 3 | 4 | 6 | 0 |
| At least 1 Grade 1-4 Lymphocytopenia | 5 | 2 | 4 | 9 | 0 |
| At least 1 Grade 1-4 Thrombocytopenia | 6 | 3 | 6 | 9 | 1 |
| At least 1 Grade 1-4 Anemia | 6 | 1 | 6 | 9 | 0 |
| At least 1 Grade 3-4 Neutropenia | 2 | 1 | 0 | 4 | 0 |
| At least 1 Grade 3-4 Leukopenia | 1 | 1 | 0 | 4 | 0 |
| At least 1 Grade 3-4 Lymphocytopenia | 4 | 0 | 1 | 5 | 0 |
| At least 1 Grade 3-4 Thrombocytopenia | 4 | 0 | 2 | 5 | 0 |
| At least 1 Grade 3-4 Anemia | 0 | 0 | 1 | 0 | 0 |
Grades (gr) 1=mild; gr2=moderate; gr3=severe; gr4=life-threatening. For details of NCI CTCAE laboratory values for each grade, please refer to http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_30. Low Potassium=Hypokalemia, High Potassium=Hyperkalemia, Low Sodium=Hyponatremia, Low Calcium=Hypocalcemia, High Bilirubin=Hyperbilirubinemia, low phosphatase=Hypophosphatemia, Low Potassium=Hypokalemia.
| participants | Dasatinib, 100 mg QD/100 mg BID + Lomustine, 110 mg/m^2 | Dasatinib, 100 mg QD/100 mg BID + Lomustine, 90 mg/m^2 | Dasatinib, 100 mg BID + Lomustine, 90 mg/m^2 | Dasatinib, 150 mg/d + Lomustine, 90 mg/m^2 | Dasatinib, 100 mg/d QD + Lomustine, 90 mg/m^2 |
|---|---|---|---|---|---|
| At least 1 Gr 1-4 Hypokalemia | 1 | 0 | 1 | 3 | 0 |
| At least 1 Gr 1-4 Hyperkalemia | 0 | 1 | 0 | 0 | 0 |
| At least 1 Gr 1-4 Hyponatremia | 1 | 0 | 0 | 0 | 0 |
| At least 1 Gr 1-4 Hypernatremia | 1 | 1 | 0 | 5 | 0 |
| At least 1 Gr 1-4 Creatinine | 0 | 2 | 0 | 0 | 0 |
| At least 1 Gr 1-4 Hypocalcemia | 3 | 1 | 3 | 2 | 0 |
| At least 1 Gr1-4 Hyperbilirubinemia | 0 | 0 | 0 | 0 | 1 |
| At least 1 Gr 1-4 Aspartate Aminotransferase / AST | 2 | 0 | 4 | 6 | 0 |
| At least 1 Gr 1-4 Hypophosphatemia | 1 | 1 | 1 | 3 | 0 |
| At least 1 Gr 3-4 Hypokalemia | 0 | 0 | 0 | 1 | 0 |
As measured by brain magnetic resonance imaging.
| participants | Dasatinib, 100 mg QD/100 mg BID + Lomustine, 110 mg/m^2 | Dasatinib, 100 mg QD/100 mg BID + Lomustine, 90 mg/m^2 | Dasatinib, 100 mg BID + Lomustine, 90 mg/m^2 | Dasatinib, 150 mg/d + Lomustine, 90 mg/m^2 | Dasatinib, 100 mg/d QD + Lomustine, 90 mg/m^2 |
|---|---|---|---|---|---|
| Number of Participants With Disease Progression at 12 Months | 6 | 3 | 7 | 9 | 1 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dasatinib, 100 mg QD/100 mg BID + Lomustine, 110 mg/m^2 | — | 5/6 (83.3%) | 6/6 (100%) |
| Dasatinib, 100 mg QD/100 mg BID + Lomustine, 90 mg/m^2 | — | 1/3 (33.3%) | 3/3 (100%) |
| Dasatinib, 100 mg BID + Lomustine, 90 mg/m^2 | — | 4/7 (57.1%) | 7/7 (100%) |
| Dasatinib, 150 mg/d + Lomustine, 90 mg/m^2 | — | 3/9 (33.3%) | 9/9 (100%) |
| Dasatinib, 100 mg/d QD + Lomustine, 90 mg/m^2 | — | 0/1 (0%) | 1/1 (100%) |
| Event | Dasatinib, 100 mg QD/100 mg BID + Lomustine, 110 mg/m^2 | Dasatinib, 100 mg QD/100 mg BID + Lomustine, 90 mg/m^2 | Dasatinib, 100 mg BID + Lomustine, 90 mg/m^2 | Dasatinib, 150 mg/d + Lomustine, 90 mg/m^2 | Dasatinib, 100 mg/d QD + Lomustine, 90 mg/m^2 |
|---|---|---|---|---|---|
| ConvulsionNervous system disorders | 0/6 | 1/3 | 1/7 | 2/9 | 0/1 |
| EnteritisGastrointestinal disorders | 0/6 | 1/3 | 0/7 | 0/9 | 0/1 |
| Platelet count decreasedInvestigations | 2/6 | 0/3 | 0/7 | 0/9 | 0/1 |
| Neutrophil count decreasedInvestigations | 0/6 | 0/3 | 0/7 | 2/9 | 0/1 |
| Subdural haematomaInjury, poisoning and procedural complications | 1/6 | 0/3 | 0/7 | 0/9 | 0/1 |
| DeathGeneral disorders | 1/6 | 0/3 | 1/7 | 0/9 | 0/1 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 1/6 | 0/3 | 0/7 | 0/9 | 0/1 |
| Decreased appetiteMetabolism and nutrition disorders | 0/6 | 0/3 | 1/7 | 0/9 | 0/1 |
| AnaemiaBlood and lymphatic system disorders | 0/6 | 0/3 | 1/7 | 0/9 | 0/1 |
| UrosepsisInfections and infestations | 0/6 | 0/3 | 1/7 | 0/9 | 0/1 |
| Event | Dasatinib, 100 mg QD/100 mg BID + Lomustine, 110 mg/m^2 | Dasatinib, 100 mg QD/100 mg BID + Lomustine, 90 mg/m^2 | Dasatinib, 100 mg BID + Lomustine, 90 mg/m^2 | Dasatinib, 150 mg/d + Lomustine, 90 mg/m^2 | Dasatinib, 100 mg/d QD + Lomustine, 90 mg/m^2 |
|---|---|---|---|---|---|
| Carbon monoxide diffusing capacityInvestigations | 0/6 | 2/3 | 3/7 | 3/9 | 1/1 |
| HeadacheNervous system disorders | 3/6 | 1/3 | 4/7 | 3/9 | 1/1 |
| FatigueGeneral disorders | 6/6 | 3/3 | 6/7 | 6/9 | 1/1 |
| VomitingGastrointestinal disorders | 4/6 | 0/3 | 3/7 | 5/9 | 1/1 |
| Exfoliative rashSkin and subcutaneous tissue disorders | 1/6 | 1/3 | 0/7 | 1/9 | 1/1 |
| Speech disorderNervous system disorders | 1/6 | 2/3 | 1/7 | 1/9 | 0/1 |
| AlopeciaSkin and subcutaneous tissue disorders | 1/6 | 2/3 | 1/7 | 1/9 | 0/1 |
| Peripheral motor neuropathyNervous system disorders | 4/6 | 1/3 | 3/7 | 5/9 | 0/1 |
| NauseaGastrointestinal disorders | 4/6 | 1/3 | 4/7 | 6/9 | 0/1 |
| Peripheral sensory neuropathyNervous system disorders | 2/6 | 2/3 | 2/7 | 1/9 | 0/1 |
| Age Continuous(years) | Dose Level 1A | Dose Level 1B | Dose Level 2 | Dose Level 3A | Dose Level 3B | Total |
|---|---|---|---|---|---|---|
| Median | 58.8 (41.3 to 70.7) | 57.7 (48.9 to 57.7) | 53.6 (42.4 to 64.0) | 49.7 (38.8 to 66.8) | 51.1 (51.1 to 51.1) | 54.8 (38.8 to 70.7) |
| Sex: Female, Male(Participants) | Dose Level 1A | Dose Level 1B | Dose Level 2 | Dose Level 3A | Dose Level 3B | Total |
|---|---|---|---|---|---|---|
| Female | 1 | 0 | 2 | 3 | 0 | 6 |
| Male | 5 | 3 | 5 | 6 | 1 | 20 |
| Histological Diagnosis of Primary Disease(participants) | Dose Level 1A | Dose Level 1B | Dose Level 2 | Dose Level 3A | Dose Level 3B | Total |
|---|---|---|---|---|---|---|
| glioblastoma multiforme | 6 | 2 | 5 | 8 | 1 | 22 |
| glioblastoma w/ oligodendroglial component | 0 | 1 | 2 | 1 | 0 | 4 |
| Eastern Cooperative Oncology Group (ECOG) Performance Status(participants) | Dose Level 1A | Dose Level 1B | Dose Level 2 | Dose Level 3A | Dose Level 3B | Total |
|---|---|---|---|---|---|---|
| Grade 0 | 6 | 2 | 1 | 4 | 1 | 14 |
| Grade 1 | 0 | 1 | 5 | 4 | 0 | 10 |
| Grade 2 | 0 | 0 | 1 | 1 | 0 | 2 |
The record gives a start of Oct 2009, a primary completion of May 2011 and a completion of May 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2012, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Aug 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Dasatinib · Lomustine